© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Finerenone stands out as a non-steroidal mineralocorticoid receptor antagonist developed for managing chronic kidney disease linked to type 2 diabetes. Chemists and researchers recognize this compound due to its specific role in blocking overactive mineralocorticoid receptors, reducing the risk of kidney and cardiovascular complications. Unlike earlier steroidal antagonists, this molecule offers a better side effect profile, making it an important step forward in nephrology and cardiology fields. Its adoption in the medical community follows well-documented clinical trials and regulatory approvals in major regions including North America, Europe, and Asia.
Finerenone’s molecular formula reads C21H21N3O3, giving a precise molecular weight of 363.41 g/mol. Its chemical structure includes a substituted dihydropyridine ring connected to a specific phenyl group, forming a solid backbone for its pharmacological interactions. The CAS Number for Finerenone is 1209333-62-3, a key identifier in chemical inventories worldwide. The compound generally appears as an off-white to pale yellow crystalline powder, with a melting point usually above 235°C, reflecting thermal stability necessary for manufacturing and storage. Under standard laboratory conditions, density measures about 1.29 g/cm³. This profile supports safe transport, reliable formulation, and allows for clear handling protocols in the pharmaceutical sector.
Solid at room temperature, Finerenone most often comes as crystalline powder. Granulation patterns reveal small flakes or fine crystals, easily distinguishable during visual inspection or simple lab analysis. The pure material presents as odorless, with no particular hygroscopic tendency, which reduces concerns about moisture absorption during storage or shipping. Although research-grade material appears as a loose, free flowing substance, certain preparations may see the powder pressed or recrystallized into denser compacts for specific analytic or formulation uses. This versatility in form supports a variety of uses, from direct pharmaceutical processing to quality control standards.
Global trade of Finerenone raw material relies on harmonized system classification. The typical HS Code associated falls within 2933.39—heterocyclic compounds with nitrogen hetero-atom(s) only. This category ensures customs and regulatory authorities quickly identify its chemical responsibilities and any tariffs or import controls. Each batch or lot produced in a GMP-compliant facility includes a certificate of analysis confirming purity (usually above 99%), structural integrity by NMR and mass spectrometry, residual solvent levels, and absence of harmful degradation products. Producers also detail storage conditions (between 2-8°C, away from direct sunlight) to maintain pharmaceutical quality and activity.
Safety data on Finerenone reflect routine chemical handling with pharmaceutical-grade precautions. Workers in manufacturing and research settings wear gloves, goggles, and laboratory coats to avoid skin and eye contact during weighing or mixing. The powdered form poses low toxicity risk at usual exposure levels, but dust inhalation should be avoided through fume hoods or sealed systems. Finerenone does not list under major chemical hazard classes such as corrosives, oxidizers, or flammables, reducing fire and environmental risks. Its stability under ambient temperatures further limits hazardous incidents during logistics. The compound remains classified for prescription use, so material transfers fall under strict documentation to prevent unauthorized or unsafe application.
Raw material supply of Finerenone links directly to its role in health systems, with demand originating from global pharmaceutical companies manufacturing finished medicines for chronic kidney disease and heart failure. Suppliers focus on consistent quality, traceable origin, and strong supply chain standards to prevent contamination and ensure authenticity. This attention to detail lowers the risk of counterfeit drugs or ineffective doses reaching clinics and hospitals. Procurement teams work closely with trusted chemical manufacturers, reviewing GMP certifications, product traceability, and independent testing before every inward dispatch.
In my early days as a researcher in medicinal chemistry, reliable data sheets for raw materials often felt like the difference between confident progress and spiraling doubts. With compounds like Finerenone, knowing exact structural, physical, and hazard details means less time troubleshooting mysterious lab errors and more time running genuine experiments. Access to clear bulk density or structural diagrams stops manufacturing hiccups long before ingredients reach the formulation tank. The global reach of Finerenone supplies puts even more emphasis on clear HS Code labelling and international compliance checks; a single missing safety note can slow down clearance at customs or disrupt months of planning. Practical transparency has more impact than any theoretical policy or spreadsheet.
A safe and well-documented chemical profile lowers workplace risks, but it also matters for environmental responsibilities. Small spills or airborne powder must be cleaned using closed systems and HEPA filtration, not standard swipe downs. Stockrooms label each container with proper hazard icons, batch numbers, and expiry dates, a practice developed from lessons learned after minor mishaps in overcrowded labs. Disposal of excess or expired Finerenone follows chemical waste protocols, keeping active pharmaceutical ingredients out of water systems. Training sessions based on real life incidents remind handlers that safety isn’t a checkbox—knowledge prevents harm and protects everyone from the manufacturing site to the end patient.
Every year, as more companies start working with Finerenone, expectations for documentation, certification, and process control rise. International regulatory updates prompt revision of product labels, shipping standards, and safety data sheets. Internal audits push for better electronic tracking, so facility managers or external inspectors can review the full history of each batch, from synthesis to shipment. Gaps in transparency usually trigger corrective action, not because of regulatory fines but due to the real world consequences seen during supply chain disruptions or product recalls. Emphasizing detail-rich, accessible information connects the dots from raw chemical to patient benefit, building trust that outlasts any single transaction or batch.
